Title: Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2015
1Alpha- Antitrypsin Deficiency - Pipeline Review,
H2 2015
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE 1 (503) 894-6022E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2 Report Overview
- Scope
- The report provides a snapshot of the global
therapeutic landscape of AlphaAntitrypsin
Deficiency - The report reviews key pipeline products under
drug profile section which includes, product
description, MoA and RD brief, licensing and
collaboration details other developmental
activities - The report reviews key players involved in the
therapeutics development for AlphaAntitrypsin
Deficiency and enlists all their major and minor
projects - The report summarizes all the dormant and
discontinued pipeline projects - A review of the AlphaAntitrypsin Deficiency
products under development by companies and
universities/research institutes based on
information derived from company and
industry-specific sources - Pipeline products coverage based on various
stages of development ranging from
pre-registration till discovery and undisclosed
stages - A detailed assessment of monotherapy and
combination therapy pipeline projects - Coverage of the AlphaAntitrypsin Deficiency
pipeline on the basis of target, MoA, route of
administration and molecule type Latest news and
deals relating related to pipeline products - Read More At http//www.researchbeam.com/alpha-a
ntitrypsin-deficiency-pipeline-review-h2-2015-mark
et
3 Table of Content
List of Tables 6List of Figures 7Introduction
8Global Markets Direct Report Coverage 8Alpha-
Antitrypsin Deficiency Overview 9Therapeutics
Development 10Pipeline Products for Alpha-
Antitrypsin Deficiency - Overview 10Pipeline
Products for Alpha- Antitrypsin Deficiency -
Comparative Analysis 11Alpha- Antitrypsin
Deficiency - Therapeutics under Development by
Companies 12Alpha- Antitrypsin Deficiency -
Therapeutics under Investigation by
Universities/Institutes 13Alpha- Antitrypsin
Deficiency - Pipeline Products Glance 14Late
Stage Products 14Clinical Stage Products
15Early Stage Products 16Alpha- Antitrypsin
Deficiency - Products under Development by
Companies 17Alpha- Antitrypsin Deficiency -
Products under Investigation by
Universities/Institutes 18Alpha- Antitrypsin
Deficiency - Companies Involved in Therapeutics
Development 19Alnylam Pharmaceuticals, Inc.
19Applied Genetic Technologies Corporation
20Arrowhead Research Corporation 21
4 Report Overview
Reasons to buy Provides strategically
significant competitor information, analysis, and
insights to formulate effective RD development
strategies Identify emerging players with
potentially strong product portfolio and create
effective counter-strategies to gain competitive
advantage Develop strategic initiatives by
understanding the focus areas of leading
companies Identify and understand important and
diverse types of therapeutics under development
for AlphaAntitrypsin Deficiency Plan mergers
and acquisitions effectively by identifying key
players of the most promising pipeline Devise
corrective measures for pipeline projects by
understanding AlphaAntitrypsin Deficiency
pipeline depth and focus of Indication
therapeutics Develop and design in-licensing
and out-licensing strategies by identifying
prospective partners with the most attractive
projects to enhance and expand business potential
and Scope Modify the therapeutic portfolio by
identifying discontinued projects and
understanding the factors that drove them from
pipeline Enquire At http//www.researchbeam.co
m/alpha-antitrypsin-deficiency-pipeline-review-h2-
2015-market/enquire-about-report
5 FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/alpha-antitrypsin-defi
ciency-pipeline-review-h2-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE 1 (800) 910-6452 DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com